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PURPOSE. To investigate the safety, acceptability, and effectiveness of light therapy on the
progression of AMD over 12 months.
METHODS. This was a phase I/IIa, prospective, proof-of-concept, single-center, unmasked
randomized controlled trial. Sixty participants (55 to 88 years) with early AMD in the study
eye and neovascular AMD (nAMD) in the fellow eye were recruited from a hospital nAMD
clinic. Eligible participants were randomized (ratio 1:1) to receive light therapy or to an
untreated control group. Light therapy was delivered via a light-emitting mask (peak 505 nm,
23 scotopic Td), which was worn each night for 12 months. Co-primary outcome measures
were disease progression (onset of nAMD or increased drusen volume beyond test-retest
limits) and change in time constant of cone dark adaptation. Other main outcomes included
adverse events, compliance, and subjective sleep quality data.
RESULTS. Disease progression over 12 months was seen in 38.1% (18.1%–61.6% confidence
interval [CI]) of intervention participants and 48.3% (29.4%–67.5% CI) of controls (Mantel-
Haenszel test, common odds ratio ¼ 0.763, P ¼ 0.495). A significantly larger delay in cone
adaptation was observed in the intervention group (1.66 6 0.61 minutes) than in the control
group (0.66 6 0.49 minutes) over the follow-up period. No reported adverse events were
deemed to be associated with the intervention.
CONCLUSIONS. Although acceptable to the patients, light therapy did not have a substantial
effect on the progression of early AMD over 12 months. Further investigation is necessary to
discover the permanency and cause of the adverse effect of light therapy on dark adaptation.
Keywords: age-related macular degeneration, light therapy, randomized controlled trial
There is a critical need to evaluate potential therapeuticinterventions aimed at treating AMD in its early stage before
the onset of advanced AMD. The pathogenesis of AMD is not
fully understood; however, there is evidence to implicate
hypoxia as a factor.1,2 Animal studies using microelectrodes to
measure the in vivo oxygen profile of the macaque retina show
that, in a healthy retina, the oxygen tension at the proximal side
of dark-adapted photoreceptor inner segments is close to
zero.3,4 This finding has been attributed to maintenance of the
‘‘dark current’’ in the retina’s approximately 92 million rods.5
Pathology-induced anatomic changes, such as disruption of
choroidal circulation,6–8 poor ocular perfusion,7,8 and changes
to Bruch’s membrane,9–11 further exacerbate the situation,
placing the retina on a ‘‘physiological knife edge.’’ The finding
of hypoxia-inducible factor in the outer retina of those with
AMD, and the upregulation of VEGF, further support the role of
hypoxia in AMD pathogenesis,12–15 whilst the functional loss
seen in patients with AMD16–21 mirrors that reported in healthy
individuals under conditions of simulated hypoxia.22–26
If outer retinal hypoxia does have a role in the pathogenesis
of AMD, treatments that mitigate this may slow or halt disease
progression. One approach would be to prevent full dark
adaptation, thereby reducing the oxygen demand.27 In practice,
this could be achieved on a nightly basis by the provision of
light therapy. Pilot studies have shown no adverse effects
associated with this approach over the course of 12 months in
people with diabetes.27,28 Furthermore, when assessing the
effect of light therapy on diabetic macular edema, a reduction
in retinal thickness after 3 months28 and an improvement in
functional measures after 6 months29 were observed. In the
present (ALight) trial, we aimed to determine whether low-level
nighttime light therapy would provide a similar therapeutic
benefit to those with early AMD.
The primary aim was to collect preliminary phase I/IIa
proof-of-concept trial data from people with early AMD in one
eye and neovascular AMD (nAMD) in the fellow eye, to
establish the safety and acceptability of the intervention and
assess the treatment effect of light therapy on disease
progression in the eye with early AMD.
METHODS
Study Design
The methods for the ALight trial are described in detail
elsewhere.30 Briefly, this was a phase I/IIa prospective proof-
of-concept, single-center, parallel-group, randomized clinical
trial conducted at Bristol Eye Hospital, Bristol, UK. Participants
were allocated to the intervention or the untreated control arm
of the trial in a 1:1 ratio. Participants randomized to light
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therapy wore a Noctura 500 organic light-emitting diode
(OLED) mask (PolyPhotonix Medical, Ltd., Sedgefield, UK; see
Fig. 1) every night for 12 months.
The trial adhered to the tenets of the Declaration of Helsinki
and was approved by the NHS National Research Ethics
Committee (13/NW/0609) and the Medicines and Healthcare
Products Regulatory Agency. An independent trial steering
committee provided oversight of the trial, and acted as a data
and safety monitoring committee.
Participants
Full eligibility criteria are available in the study protocol.30 In
brief, participants were between 55 and 88 years with early
AMD in the study eye and nAMD in the fellow eye. An Early
Treatment of Diabetic Retinopathy Study (ETDRS) best
corrected visual acuity (BCVA) of 0.3 logMAR or better was
required for the study eye and the participant had to be within
a month of their third ranibizumab injection in the fellow eye.
To improve a lower than projected recruitment rate, an
amendment was made to the eligibility criteria 6 months after
trial inception to include those who were outside their 3-
month ranibizumab loading phase at the time of baseline
assessment. Participants were excluded if they had an ocular
condition other than macular disease, were taking medication
known to affect visual function, had a systemic condition that
would compromise participation in a 12-month study, had
insufficient English language comprehension to complete the
questionnaires, had a cognitive impairment, wore an oxygen
mask at night, or were unwilling to adhere to the allocated
treatment for the duration of the trial. In addition, a
participant’s inclusion in the study was suspended if the
subject wished to discontinue, exhibited an unexpected
change in clinical status, or if a serious adverse event arose
(for example, conversion to nAMD in the study eye).
Study Protocol
The study flow diagram in Figure 2 outlines the appointment
schedule. Screening assessment involved a standardized
examination procedure, including documenting ocular and
medical history and current medication, assessment of logMAR
BCVA using the ETDRS test chart, and a clinical eye
examination. An abridged version of the Mini-Mental State
Examination was used to screen for cognitive impairment.31
Self-reported visual function was also measured using the
Veterans Affairs Low Vision Visual Function Questionnaire
(VFQ-48),32 and health-related quality of life with the EuroQol-
5D Instrument (EQ-5D).33
Procedures conducted at baseline included optical coher-
ence tomography (OCT) imaging (five 63 6-mm macular cube
scans; Zeiss Cirrus SD-OCT 4000 [Carl Zeiss Meditec, Inc.,
Dublin, CA, USA]) to derive drusen volume measurements
(within a 5-mm-diameter circle), color fundus photography
(308-diameter images centered on the fovea; Topcon 3D-OCT
2000 [Topcon Medical Systems, Inc., Oakland, NJ, USA]), BCVA
measurement (ETDRS number of letters read), chromatic
threshold measurement (Color Assessment and Diagnosis Test
[CAD],18 version 2.2.4. [City Occupational Ltd., London, UK]),
14-Hz flicker threshold measurement, dark adaptation assess-
ment (28-radius solid yellow circular stimulus), and a self-
reported sleep quality questionnaire (Pittsburgh Sleep Quality
Index [PSQI]).34 The experimental procedures used for
functional tests have been published elsewhere.17,35 Following
baseline data collection and randomization, drusen volume and
PSQI data were collected for both study groups on a monthly
basis for 12 months. The final visit was the same as the baseline
visit with the addition of the VFQ-48 and EQ-5D.
Fundus images were graded according to the Age-Related
Eye Disease Study (AREDS) Simplified Severity Scale36 by two
independent graders. Randomization was performed immedi-
ately following baseline data collection as described in the
study protocol.30 Briefly, computer-generated random permut-
ed blocks (block size randomly varied among 2, 4, and 6)
stratified for AMD severity grade were used to randomize the
participants. Each stratum was distributed in three separate
piles of sealed, numbered envelopes by the chief investigator.
The envelopes belonging to each AMD stratum were used in
numerical order by the trial investigator to allocate participants
to a study group.
The trial investigator and participants were not masked to
the randomization group during this study. It was not possible
to mask the trial investigator, as his duties involved not only
collecting outcome data, but also providing the intervention
light masks as well as instruction on usage, and guidance
regarding any issues with the masks throughout the trial.
Treating ophthalmologists reviewing participants for ranibizu-
mab injections were masked to the treatment arm to prevent
bias in retreatment decisions for the fellow eye.
Intervention
Participants randomized to the intervention arm were given a
Noctura 500 OLED mask for nightly usage. When activated via
a touch sensor, the light sources emitted a dim green light
(peak output 505 nm). When adjusted for the average eye lid
transmission (assumed as 1%),37–39 and pupil diameter
(approximately 4 mm in the age group 60–85 years),40 this
equated to a retinal illuminance of approximately 23 scotopic
FIGURE 1. Principal components of the OLED sleep mask. The left panel shows the light-emitting ‘‘pod’’ of peak output 505 nm. The right panel
shows the cushioned fabric mask that houses the pod.
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Trolands. This was estimated to reduce the rod-circulating
current by 40%, thus diminishing the eye’s oxygen require-
ments.29 The masks were programmed at the time of issue to
function for a maximum of 8 hours within a predetermined
time window (20:00 to 10:00). Once activated, the mask would
remain lit for the 8-hour treatment period. Compliance data,
based on capacitive sensing, were recorded automatically,
stored on a chip within the mask, and extracted from the mask
monthly. To ensure consistent luminance throughout the trial
the light source was replaced every 3 months.
Outcome Measures
The study included two co-primary outcome measures,
reflecting structural and functional status: (1) the proportion
of people showing disease progression in the eye with early
AMD over 12 months based on the onset of advanced AMD or
an increase in drusen volume beyond test-retest 95% confi-
dence intervals (95% CIs),41 and (2) the change in cone s (time
taken for cone photoreceptors to recover their sensitivity to
approximately 63% of the pre-bleach value after being exposed
to a bright adapting light). Outcome measures used to assess
the safety and acceptability of the intervention included 12-
month objective mask compliance data, change in self-reported
sleep disturbance (PSQI), and adverse events related to the
intervention. Secondary outcome measures included the 12-
month change in drusen volume. chromatic threshold, BCVA
ETDRS number of letters read, flicker threshold, self-reported
visual function (VFQ-48), and health-related quality of life (EQ-
5D), and the ranibizumab retreatment rate in the fellow eye
(assessed through review of medical records at the end of 12
months).
Analysis
An available-case analysis was performed using IBM SPSS
Statistics (SPSS for Windows, Version 20.0; SPSS Inc., IBM
Corp., Chicago, IL, USA). No interim analysis was performed.
As this was an exploratory study, we aimed to recruit 60
participants that, allowing for 15% dropout throughout the
year,29 was expected to leave a final cohort of 51. Details of the
sample size calculation can be found in the trial protocol.30 In
FIGURE 2. Study flow diagram showing participant timeline. It was anticipated that sixty participants would be recruited, who had nAMD and were
scheduled for three ranibizumab injections over a 3-month period within the nAMD clinic (nAMD clinic visit 1–3). Participants recruited after the
amendment of the protocol did not have to be within the 3-month loading phase to enroll in the trial. Bracketed number of trial information sheets
distributed, participants excluded following screening, and participants at the 12-month nAMD clinic appointment show projected figures before
trial inception. Adapted from McKeague C, Margrain TH, Bailey C, Binns AM. Low-level night-time light therapy for age-related macular degeneration
(ALight): study protocol for a randomized controlled trial. Trials. 2014;15:246.
Low-Level Nighttime Light Therapy for AMD IOVS j September 2018 j Vol. 59 j No. 11 j 4533
Downloaded From: https://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/937492/ on 01/07/2019
accordance with the consensus relating to randomized
controlled trials, differences in baseline characteristics be-
tween groups were not assessed.42,43 Descriptive statistics
were used to summarize participant demographics, as well as
the proportion of individuals showing disease progression in
each group (695% CIs using ‘‘exact’’ calculation) and the
magnitude of changes in secondary outcome measures. The
primary outcome measure (proportion demonstrating disease
progression at 12 months) was assessed using a stratified
Mantel-Haenszel test. Analysis of covariance (ANCOVA) com-
pared the 12-month change in cone s, BCVA, and the
ranibizumab retreatment rate between the study groups. Age,
sex, ocular supplement intake, history of smoking, and
baseline data relating to each outcome measure were
covariates. A Kruskal-Wallis test was used to compare the 12-
month change in drusen volume, flicker threshold, and red-
green (RG) and yellow-blue (YB) chromatic threshold data,
which remained nonparametric even after log transformation.
PSQI, VFQ-48, and EQ-5D questionnaires were scored using
established scoring systems.34,44–46 In accordance with present
consensus regarding Likert scale analysis,47–50 12-month
changes in questionnaire data between study groups were
analyzed with parametric (ANCOVA; PSQI) and nonparametric
(Kruskal-Wallis; VFQ-48 and EQ-5D) tests as appropriate.
RESULTS
Participant Characteristics
Thirty intervention and 30 control participants were recruited
from July 2014 to November 2015. Each participant was
reviewed monthly over a year (average time on study 6 SD,
372.00 6 18.59 days). All participants exhibited early AMD
(soft drusen and/or focal pigmentary changes) in one eye and
nAMD in their fellow eye (confirmed by fluorescein angiogra-
phy). During the course of the trial, no participant exhibited
lenticular opacification greater than grade 1 according to any
parameter on the Lens Opacity Classification System.51
Descriptive statistics of each study group are shown in Table 1.
Primary Outcome Measures
Characteristics relating to the change in drusen volume of
those who completed the study are shown in Table 2. One
intervention participant and two controls progressed to nAMD
during the course of the study. When combined with those
who showed significant drusen growth, 38.1% (n ¼ 8, 8.1%–
61.6% CI) of the intervention and 48.3% (n¼ 14, 29.4%–67.5%
CI) of the control group showed disease progression over the
course of the trial. Although the risk of disease progression was
reduced in the intervention group, this did not reach statistical
significance (Mantel-Haenszel test, Common Odds Ratio ¼
0.763, P¼0.495). Considering disease progression on the basis
of change in dark adaptation, slower cone s values relate to a
greater deficit in dark adaptation. When measured after 12
months, the mean cone s of the mask-wearers and controls was
slower than initially recorded (by 1.59 and 0.70 minutes,
respectively) suggesting a worsening over the study duration.
Over 12 months, the delay in cone s was significantly greater
(P = 0.018) in the intervention group (1.66 6 0.61 minutes)
than in the control group (0.66 6 0.49 minutes) when
adjusted for covariates (see Fig. 4).
Safety of the Intervention
During the course of the study, 33 adverse events (AEs) were
recorded. Eight ocular AEs were recorded (four control, four
intervention), of which two occurred as a direct result of
ranibizumab administration. Nineteen AEs were related to
general health issues and six (five control, one intervention)
were related to falls (all of which occurred during daylight
hours). Nine serious AEs (SAEs) were reported. Three related
to the onset of nAMD in the study eye and five were attributed
to changes in general health. No AE or SAE was deemed to be
associated with the intervention. It should be noted, however,
that the treatment group exhibited a significantly greater delay
in cone dark adaptation over the year than the control group
(see primary outcome measure analysis).
Acceptability of the Intervention and Compliance
to Mask Wear
Figure 3 details the number of participants who left the trial,
with reasons. The mean (6SD) number of days of mask wear
before withdrawal was 61 (643). Details of reported interven-
tion discomfort issues are outlined in Table 3. All discomfort
issues relating to the temples, nasal bridge, and eyelash
irritation tended to be reported for the duration of the trial.
Facial overheating was primarily seasonal, and issues with
fabric housing odor of newly issued masks resolved within 1
week. At first exposure, the light level was well tolerated by
more than 90% of the cohort. For those who completed the
TABLE 1. Baseline Descriptive Statistics for Participants
Participant Characteristic
Intervention Control
Full Cohort
Completed Study
Cohort Full Cohort
Completed Study
Cohort
Number of participants 30 (60% female) 21 (43% female) 30 (53% female) 29 (48% female)
Mean age (6SD) 78.30 (66.56) 78.43 (67.03) 77.17 (66.95) 77.00 (67.02)
AREDS grade 2, n 9 6 9 9
AREDS grade 3, n 13 9 9 8
AREDS grade 4, n 8 6 12 12
Mean BCVA study eye, ETDRS letters read (6SD) 50.63 (66.49) 50.76 (66.54) 51.10 (66.24) 51.07 (66.35)
Mean BCVA fellow eye, ETDRS letters read (6SD) 35.53 (615.44) 34.95 (614.74) 33.90 (616.10) 34.03 (616.36)
Number currently taking ocular supplements (% of cohort) 11 (36) 7 (33) 6 (20) 7 (24)
Ocular supplement history, mean years taken (6SD) 0.93 (61.29) 0.76 (61.38) 0.32 (60.63) 0.33 (60.63)
Smoking history, mean pack years (6SD) 13.89 (620.07) 12.43 (620.21) 12.42 (618.50) 12.68 (618.77)
Characteristics are shown for the entire cohort (full cohort) and those who completed the 1-year study duration or withdrew as a result of nAMD
onset in the study eye (completed study cohort). Twenty-one intervention and 29 control participants either completed the trial or withdrew as a
result of nAMD onset in the study eye, and are included in the magnitude of effect analysis (see Fig. 3). Those who completed the full study period
(20 intervention, 27 control) are included in the secondary outcome analysis.
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entire study, the average compliance based on the objectively
measured hours of mask wear per night and self-reported mean
number of hours sleep per night (7.19 6 0.89) was 78%
(623% CI). No significant difference (P > 0.05) in mean hours
of mask use per month was found over the study duration.
When assessing self-reported sleep disturbance over the study
duration, no significant difference in change of PSQI global
score was found between groups (P ¼ 0.19).
Secondary Outcome Measures
There was no significant difference in median change in
functional or self-reported secondary outcome measures
between study groups (see Figs. 4, 5; Supplementary Table
S1). Twenty-one participants (10 intervention, 11 control)
were recruited within their initial ranibizumab loading phase.
Ranibizumab use was ceased in favor of aflibercept for seven
participants (four intervention, three control) during the
course of the study. No significant difference (P ¼ 0.30) was
found between the mean (6SD) number of anti-VEGF
injections received over 12 months by the intervention (5.28
6 2.54) and control (4.38 6 2.91) groups (Fig. 4; Supplemen-
tary Table S2).
Protocol Violations
For six participants (four control, two intervention), final visits
were conducted outside the proposed timescale of 12 months
(64 weeks). The intervention participants within this group
were 6 and 7 days over the 12-month (64-week) schedule and
continued to wear the mask through this additional period.
Due to a malfunction of the Zeiss Cirrus SD-OCT 4000 for a 9-
week period, drusen volume data were not collected over two
consecutive monthly follow-up visits for 24 participants.
During this period end-of-study appointments for five partic-
ipants (four intervention, one control) were still conducted in
accordance with the protocol. Following the end-of-study visit,
mask wear was ceased and missing data were collected as soon
as possible thereafter. The mean delay in drusen volume
measurement was 7.20 (6 2.89) weeks post final study visit.
DISCUSSION
The findings of this study suggest that low-level nighttime light
therapy, although acceptable to the patients, does not have a
large effect on drusen progression or progression to nAMD in
patients with early AMD over 12 months. Although a greater
proportion of controls than mask-wearers showed disease
progression over the trial, this difference failed to reach
significance. It must, however, be noted that this was an
exploratory study, and as such was not powered to detect small
differences between study groups. Post hoc sample size
calculations suggest that a sample size of 381 per group would
be required to detect an effect of the magnitude seen in this
trial (80% power, P ¼ 0.05) at 12 months.
In the present study, the only outcome measure to show a
significantly different change over 12 months between the
study groups was dark adaptation. There is an emerging body
of evidence to suggest that dark adaptation is a sensitive
biomarker of AMD,16,17,21,52–60 although there are limited
longitudinal data to show the sensitivity of the test to disease
progression,56,61 particularly when used over a 1-year as
opposed to a 2-year period.62 Cone adaptation was selected
rather than rod adaptation as an outcome measure in this study
primarily for pragmatic reasons. Assessment of rod adaptation
for a longitudinal study can be time-consuming and fatiguing
for the participant, whereas cone adaptation may be evaluated
more rapidly. For example, in a study investigating the dark
adaptation characteristics of individuals with intermediate
AMD, where time taken to reach a criterion threshold on the
second component of rod recovery was measured, nearly a
third of individuals required longer than 30 minutes, with
recovery times ranging from 8.8 to 124.4 minutes.62 There is
substantial evidence to suggest that, despite the proposed
alternative mechanism for photopigment regeneration avail-
able to cones through the Mu¨ller cell pathway,63,64 cone
adaptation is also adversely affected by AMD disease progres-
sion.17,21,52,53,58,59,65
The significant increase in cone s seen in the intervention
group when compared with the controls suggests that cone
adaptation was selectively impaired in the treatment group.
However, there are no published data regarding the long-term
effect of reducing the rod-circulating current on the dynamics
of cone adaptation. Hence, although the delayed dark
adaptation metric may herald the development of early AMD,
it is also possible that it is a consequence of disrupting retinal
physiology. It would be useful to evaluate this effect before any
future phase 3 trials of efficacy are initiated into this treatment
to further evaluate the safety of the intervention. For example,
a short-term study evaluating the time course and longevity of
any effect of the intervention on rod and cone dark adaptation
rates both in people with and without pathology would be
valuable.
The proposed aim of this treatment to moderate retinal
physiology might be considered to be analogous to other
putative interventions that have aimed to reduce the progres-
sion rate of dry AMD through modulating the visual cycle. For
example, fenretinide (4-hydoxy[phenyl]retinamide) is a reti-
noid derivative that competes with retinol for binding to
retinol binding protein 4 (RBP4), thus reducing the delivery of
all-trans-retinol to the RPE.66,67 In contrast, the treatment
emixustat (a derivative of all-trans-retinylamine) is a retinol
mimic that inhibits the action of isomerohydrolase RPE65,
TABLE 2. Drusen Volume Characteristics of Each Study Group
Change in Drusen
Intervention Control
n (%) Mean (6SD) n (%) Mean (6SD)
Growth 8 (40.0) 0.012 (60.006) 16 (59.2) 0.018 (60.030)
Significant growth 7 (35.0) 0.013 (60.005) 12 (44.4) 0.027 (60.035)
Shrinkage 5 (25.0) 0.036 (60.047) 5 (18.5) 0.018 (60.024)
Significant shrinkage 5 (25.0) 0.036 (60.047) 4 (14.8) 0.022 (60.025)
No change 7 (35.0) 0.000 (60.000) 6 (22.2) 0.000 (60.000)
Percentages given relate to total number in each cohort that completed the entire study duration (intervention, 20; control, 27). ‘‘Growth/
shrinkage’’ defines participants for whom an increase/decrease in drusen volume was reported over 12 months. ‘‘Significant growth/shrinkage’’
defines those for whom the increase/decrease in drusen volume was outside 95% test-retest CIs as derived from Gregori et al.41 ‘‘No change’’ defines
those who had the same drusen volume at baseline and final study visits.
Low-Level Nighttime Light Therapy for AMD IOVS j September 2018 j Vol. 59 j No. 11 j 4535
Downloaded From: https://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/937492/ on 01/07/2019
FIGURE 3. CONSORT flow diagram showing participant recruitment and follow-up (www.consort-statement.org/), with reasons for withdrawal at
each stage.
TABLE 3. Reported Issues Relating to Intervention Discomfort
Subjective Feedback Reported, n Withdrawn, n
Discomfort to temples 10 3
Facial overheating 6 1
Eyelid/eyelash irritation 2 1
Intolerance to light level 2 0
Discomfort to nasal bridge 9 3
Intolerance to odor of fabric housing 3 0
Intolerance to general sensation of mask wear 3 0
Intolerance to mask displacement during sleep 8 0
Increased dreaming since inception of mask wear 1 0
Increased periorbital darkening since inception of mask wear 1 0
The reported column specifies the total number of participants reporting each issue. The withdrawn column specifies the number of
participants withdrawn from study reporting each reason as a key factor for their removal from study.
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which is responsible for generating 11-cis retinol from all-trans-
retinyl ester in RPE cells.67,68 The hypothesis with both of
these treatments, and other visual cycle modulating agents, is
that, through slowing the visual cycle and the consequent
reduction in formation of the toxic bisretinoid fluorophore
A2E found in RPE lipofuscin, AMD progression will be
slowed.66,67,69–71 Trial results for fenretinide did not show a
statistically significant difference in geographic atrophy lesion
size compared with placebo and the trend toward reduced
lesion growth rates in those where RBP levels dropped below 2
mg/dL was also not statistically significant.66 Similarly, a phase
2b/3 trial of emixustat in the treatment of geographic atrophy
failed to reach its primary endpoint.71 In common with the
current study, these interventions resulted in an apparent (but
not symptomatic) delay in dark adaptation72,73; however, the
mechanism of action is very different. That is, the low-level
FIGURE 4. Mean plots showing change in rate of cone retinal adaptation (cone s) (a) and BCVA (b, c) over 12 months. Plots (d) and (e) show the
number of anti-VEGF injections administered over the study duration for the entire study cohort (d) and those recruited within their loading phase
only (e). Black circles represent total injections (ranibizumab and aflibercept) and white circles represent those treated only with ranibizumab for
the study duration. Whiskers denote 95% CIs. *Parameters that demonstrate a significant difference between study groups.
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light therapy aims to reduce the oxygen demand of the retina
by reducing the dark current, so alleviating hypoxia, rather
than targeting bisretinoid accumulation in the RPE and the
associated photo-oxidative damage. The efficacy of these
different modes of treatment is not, therefore, likely to be
directly comparable.
In this study, we found the potential influence of light
therapy on ranibizumab retreatment rate to be limited.
However, the variation in how long patients had been on
treatment at the start of the study is likely to have been a key
confounding factor. As retreatment rates were generally low,
this will have further affected any likelihood of significant
reductions being observed.
The retinal illuminance provided by the mask was well
tolerated by 90% of participants. The overall withdrawal rate as
a result of mask issues alone (26%) and compliance rate (70%)
were in agreement with data reported by Sahni et al.28
(withdrawal rate, 21%; compliance rate, 76%), in which a
similar intervention was assessed in patients with diabetic
macular edema (n ¼ 15) and healthy controls over two age
groups (18–30 years, n¼ 45 and 50–70 years, n¼ 24). As 75%
of withdrawals caused by mask issues occurred within 64 days
FIGURE 5. Boxplots showing 12-month change in RG chromatic threshold (a), YB chromatic threshold (b), 14-Hz flicker threshold (c), drusen
volume (d), VFQ-48 person measure (e), and EQ-5D score (f). For change in drusen volume, three outliers (two control [0.058, 0.120] and one
intervention [0.120]) have not been included, to aid visualization.
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post randomization, future studies may expect a low with-
drawal rate beyond 3-months wear.
In the present study, disruption to compliance was minimal
and primarily caused by ranibizumab administration. The
complaints relating to mask discomfort reported by those
who had completed the full study duration were not reflected
in the PSQI analysis of sleep quality. According to data obtained
with the PSQI, the nightly delivery of low-level light therapy
had no measurable effect on sleep quality (duration or latency).
This is in agreement with other studies that also reported no
SAEs associated with mask wear.27–29
The strengths of the study include the robust randomized
controlled trial design, the successful masking of treating
ophthalmologists, the high level of compliance, and the
relatively low rate of withdrawal after the initial period of
adaptation. A weakness was that an eligibility criteria change
was required to improve the recruitment rate, thus potentially
reducing the power of the analysis with respect to rate of
injection in the eye with nAMD. This study focused on
progression defined by increased drusen volume or conversion
to nAMD. It may be valuable for any future trial to also include
the development or progression of atrophic changes. A further
major limitation of the trial with respect to the assessment of
efficacy was the small sample, which was appropriate for a
phase I/II safety evaluation but was powered only to detect a
relatively large effect size.
In conclusion, this exploratory study has collected impor-
tant information about the safety and acceptability of the OLED
sleep mask in this patient cohort and the potential magnitude
of the treatment effect for powering future trials. Further phase
I and II trials are required to explore the finding of a greater
delay in cone dark adaptation in the treated group, to
determine the origin and longevity of this effect, and to
investigate the potential safety implications of this finding.
Thereafter, assuming that the safety issues are addressed, a
larger cohort will be required to determine whether the small
(statistically insignificant) effect of the intervention on risk of
progression of early AMD at 12 months was a chance finding.
Further work is also required to determine the potential effect
of the treatment on the progression and retreatment rates for
nAMD, as well as the possible effect of treatment extending
beyond 12 months.
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